Benjamin T. Dake - 18 Mar 2024 Form 4 Insider Report for Aerovate Therapeutics, Inc. (JBIO)

Signature
/s/ George A. Eldridge, Attorney-in-Fact
Issuer symbol
JBIO
Transactions as of
18 Mar 2024
Net transactions value
-$710,209
Form type
4
Filing time
20 Mar 2024, 18:00:17 UTC
Previous filing
24 Jan 2024
Next filing
27 Mar 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction AVTE Common Stock Options Exercise $43,992 +20,557 +1592% $2.14* 21,848 18 Mar 2024 Direct F1
transaction AVTE Common Stock Options Exercise $153,845 +14,500 +66% $10.61* 36,348 18 Mar 2024 Direct F1
transaction AVTE Common Stock Sale $707,282 -27,476 -76% $25.74 8,872 18 Mar 2024 Direct F1, F2
transaction AVTE Common Stock Sale $200,764 -7,581 -85% $26.48 1,291 18 Mar 2024 Direct F1, F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction AVTE Stock Option (Right to Buy) Options Exercise $0 -20,557 -17% $0.000000 102,789 18 Mar 2024 Common Stock 20,557 $2.14 Direct F1, F4
transaction AVTE Stock Option (Right to Buy) Options Exercise $0 -14,500 -25% $0.000000 43,500 18 Mar 2024 Common Stock 14,500 $10.61 Direct F1, F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 16, 2023.
F2 The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $25.235 to $26.234, inclusive. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
F3 The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $26.25 to $26.88, inclusive. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
F4 A total of 328,921 shares subject to an employee stock option were granted on April 2, 2021, with the first installment vested on July 4, 2021, and with shares vesting in 48 substantially equal monthly installments.
F5 A total of 58,000 shares subject to an employee stock option were granted on December 14, 2021, with the first installment vested on January 14, 2022, and with shares vesting in 48 substantially equal monthly installments.

Remarks:

Officer Title: President, Chief Operating Officer and Secretary